WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 14, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
today announced that Douglas Seith will assume the role of Chief
Operating Officer. Mr. Seith will now be responsible for all global
commercial organizations as well as education and clinical science
programs. The company also announced that Andy Wade has been promoted to
Senior Vice President and Chief Financial Officer.
Mr. Seith has over 25 years of cardiology and general surgery sales and
sales leadership experience and has served as AtriCure’s Senior Vice
President, Sales and Marketing since January 2013. Since joining
AtriCure in 2004, Mr. Seith has held a variety of progressive sales and
sales leadership positions. Prior to joining AtriCure, Mr. Seith held
sales leadership or sales positions with A-Med/EmoblX, Inc., where he
was the Vice President of Sales, Heartport, Inc., Scimed Life Systems (a
division of Boston Scientific, Inc.) and Automated Instruments (a
division of United States Surgical Corporation).
“Doug is an exceptional executive who has strong customer skills as well
as keen clinical and technical capabilities,” said Mike Carrel,
President and Chief Executive Officer of AtriCure. “In his decade plus
tenure at AtriCure, he has helped lead the company’s remarkable and
consistent growth. His leadership has been paramount to our success and
I have confidence that his innovative thinking and vision will continue
to enhance the strategic direction and growth of the Company.”
Mr. Carrel continued, “Andy has served as our Vice President and Chief
Financial Officer since 2013, and possesses a particularly impressive
track record over the course of his seven years at AtriCure. Some of his
many accomplishments include leading two public financings in the span
of 13 months, raising over $125 million in the process, while supporting
our growth and the integration of Estech. It is because of these and
many important contributions as well as his leadership strengths that
Andy has been promoted to Senior Vice President,” said Mike Carrel.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of Persistent and Longstanding Persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip Left Atrial Appendage Management (LAAM) exclusion
device is the most widely sold device worldwide that’s indicated for the
occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. Afib affects more than 33.5 million people worldwide.
Source: AtriCure, Inc.
AtriCure, Inc.
Andy Wade, 513-755-4564
Senior
Vice President and Chief Financial Officer
awade@atricure.com
or
Investor
Relations:
Westwicke Partners
Lynn Pieper, 415-202-5678
Lynn.pieper@westwicke.com
